Uveitis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • ID: 4340269
  • Report
  • 125 pages
  • P&S Market Research
1 of 3
Disease Overview

Uveitis is a chronic inflammatory disease which causes swelling and pain in eye tissues, mainly uvea. It also affects the retina, lens, vitreous and optic nerve, thus hampering the vision of a person. The chances of vision being affected depends on the severity of the disease. People in the age group of 20 to 60 years are most affected by this disease. The severity of the disease can vary from acute to chronic. The different types of uveitis based on the location of the affected tissue includes anterior uveitis, intermediate uveitis, posterior uveitis and panuveitis uveitis. Uveitis is mainly caused by any infection, toxins which penetrate in the eye, or any bruise to the eye or due to an attack from the body’s own immune system. Uveitis can be associated with many diseases including behcet’s syndrome, ankylosing spondylitis, psoriasis, ulcerative colitis, multiple sclerosis, herpes zoster infection, rheumatoid arthritis and others.

Uveitis includes symptoms such as blurred vision, dark, floating spots in the vision, redness in the eye, pain and sensitivity to light. The disease is diagnosed by examining the symptoms and eye examination, which includes an eye chart or visual acuity test, a funduscopic exam, ocular pressure and a slit lamp exam. Uveitis is treated by first eliminating inflammation, alleviating pain, preventing further tissue damage and restoring any loss of vision. Treatments depend on the type of uveitis a patient displays. Some, such treatments include, using corticosteroid eye drops and injections around the eye or inside the eye, may exclusively target the eye whereas other treatments, such as immunosuppressive agents, taken by mouth, may be used when the disease is occurring in both eyes, particularly at the back of both eyes. The treatment usually includes steroidal anti-inflammatory medication.

Various advancements in technologies at cellular and molecular level are driving the growth of uveitis therapeutics pipeline. Also, drug manufacturing companies are using various promising targets for the treatment of the disease. Targeted therapy is more effective in achieving good results. The potential targets will possibly stop or slow the progression of the disease with better efficacy and lesser side effects.

Pipeline Analysis

As of May 2017, the uveitis pipeline comprises approximately 33 active drug candidates in different stages of development.

Uveitis Therapeutics Pipeline Analysis

Competitive Landscape

Some of the key players developing drugs for the treatment of uveitis include Aldeyra Therapeutics, Inc., EyeGate Pharmaceuticals, Inc., pSivida Corp. and others.

Scope for Customization

Customization is offered as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

Market Forecast - Market analysis and forecast for the drug candidates in the latest stage of development
Company Profiles - Wider company coverage in terms of detailed analysis or additional company profiles
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research

3. Executive Summary

4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.3 Key Barriers
4.4 Uveitis Pipeline Analysis
4.4.1 Pipeline Analysis By Phase
4.4.2 Pipeline Analysis By Target
4.4.3 Pipeline Analysis By Route Of Administration
4.4.4 Pipeline Analysis By Molecule Type
4.4.5 Pipeline Analysis By Company

5. Uveitis Pipeline Analysis By Phase (2017)
5.1 Phase Iii: Drug Profiles
5.1.1 Pre-Clinical Study
5.1.2 Pre-Clinical Results
5.1.3 Clinical Trials
5.1.4 Clinical Results
5.1.5 Strategic Development
5.1.6 Designation
5.1.7 Grants
5.1.8 Patent
5.1.9 Technology
5.2 Phase Ii: Drug Profiles
5.2.1 Pre-Clinical Study
5.2.2 Pre-Clinical Results
5.2.3 Clinical Trials
5.2.4 Clinical Results
5.2.5 Strategic Development
5.2.6 Designation
5.2.7 Grants
5.2.8 Patent
5.2.9 Technology
5.3 Phase I: Drug Profiles
5.3.1 Pre-Clinical Study
5.3.2 Pre-Clinical Results
5.3.3 Clinical Trials
5.3.4 Clinical Results
5.3.5 Strategic Development
5.3.6 Designation
5.3.7 Grants
5.3.8 Patent
5.3.9 Technology
5.4 Pre-Clinical: Drug Profiles
5.4.1 Pre-Clinical Study
5.4.2 Pre-Clinical Results
5.4.3 Strategic Development
5.4.4 Designation
5.4.5 Grants
5.4.6 Patent
5.4.7 Technology
5.5 Discovery: Drug Profiles
5.5.1 Strategic Development
5.5.2 Designation
5.5.3 Grants
5.5.4 Patent
5.5.5 Technology

6 Competitive Landscape
6.1 Key Players Benchmarking For Uveitis Drug Candidates
6.2 Swot Analysis Of Uveitis Pipeline

7 Company Profiles
7.1 Business Overview
7.2 Product And Service Offerings

8 Appendix
8.1 Abbreviations

List Of Tables
Pipeline Analysis Of Uveitis, By Company (2017)
Description Of Phase Iii Drug Candidates
Clinical Trials Of Phase Iii Drug Candidates
Description Of Phase Ii Drug Candidates
Clinical Trials Of Phase Ii Drug Candidates
Description Of Phase I Drug Candidates
Clinical Trials Of Phase I Drug Candidates
Description Of Pre-Clinical Drug Candidates
Description Of Discovery Drug Candidates
Companies- At A Glance

List Of Figures
Research Methodology For The Uveitis Pipeline Analysis
Split Of Primary And Secondary Research
Breakdown Of Primary Research Respondents, By Industry Participants
Breakdown Of Primary Research Respondents, By Company Type
Number Of Uveitis Drug Candidates Under Development (2017)
Uveitis Pipeline Split, By Target (2017)
Uveitis Pipeline Split, By Route Of Administration (2017)
Uveitis Pipeline Split, By Molecule Type (2017)
Key Players Benchmarking For Uveitis Drug Candidates
Swot Analysis Of Uveitis Pipeline
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll